Although MRI examinations in patients with retained temporary epicardial leads, which consist of electrically conductive material, could theoretically lead to cardiac excitation or thermal injury, such leads are relatively short in length, usually do not form large loops, and are generally not believed to pose a significant risk during MRI procedures.
Although MRI examinations in patients with retained temporary epicardial leads, which consist of electrically conductive material, could theoretically lead to cardiac excitation or thermal injury, such leads are relatively short in length, usually do not form large loops, and are generally not believed to pose a significant risk during MRI procedures.
Hartnell et al reported on 51 patients with retained temporary epicardial pacing wires who underwent clinical MRI procedures. Of those patients examined with electrocardiographic monitoring, no arrhythmias were noted. For all patients, no symptoms suggestive of arrhythmia or other cardiac dysfunction were noted, although the anatomic region examined and the energies used in the examinations were not specifically described.
To date, there is no report of complications associated with performing MRI in a patient with retained epicardial leads.
By comparison, one ex vivo study of temporary intracardiac transvenous pacing leads reported temperature increases of up to 63.1°C. Preliminary results of a recent study confirmed that even unconnected temporary transvenous pacing (as well as permanent pacing) leads can undergo high temperature increases at 1.5T.
In a chronic pacemaker animal model undergoing an MRI examination at 1.5T, temperature increases of up to 20°C were measured, although pathological and histological examination did not demonstrate heat-induced damage of the myocardium. The MRI conditions that generated such elevated lead temperatures included use of the body radiofrequency coil to transmit RF energy over the area of the intracardiac pacing lead (e.g., an MRI examination of the chest/thorax).
To the best of our knowledge (i.e., the Consensus Group: Levine GN, Gomes AS, Arai AE, et al), there are no studies assessing the safety of temporary pacemakers (lead and external pulse generator). Unlike permanent devices, temporary pacemakers use unfixed leads that are more prone to movement, longer leads that may be more prone to induction of lead currents, and a less sophisticated pulse generator, which makes them more susceptible to electromagnetic interference.
Thus, patients with retained temporary epicardial pacing wires are considered able to safely undergo MRI procedures, and patients do not need to be routinely screened for the presence of such wires before scanning. Because of the possible risks involved with temporary pacemaker external pulse generators, however, such generators should not be introduced into the MRI environment.
Although temporary intracardiac transvenous lead heating may be minimized or avoided by scanning anatomic regions above (e.g., head/brain) or below (e.g., lower extremities) the cardiac pacing leads, scanning of patients with temporary intracardiac pacing leads (without the generator) is not recommended. Furthermore, because the harsh electromagnetic environment associated with the MR system can alter the operation of an external pulse generator or damage it, it may not be possible to reliably pace the patient during the MRI examination, which makes the issue of scanning a patient with a temporary intracardiac transvenous lead irrelevant in most cases.
*[Excerpted with permission from Levine GN, Gomes AS, Arai AE, et al. Safety of magnetic resonance imaging in patients with cardiovascular devices: an American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization. Circulation 2007;116:2878-2891.]
Dr. Shellock is an adjunct clinical professor of radiology and medicine at the Keck School of Medicine of the University of Southern California in Los Angeles. He is also an adjunct professor of clinical physical therapy in the division of biokinesiology and physical therapy at USC and is president of Shellock R&D Services.BIBLIOGRAPHY
Achenbach S, Moshage W, Diem B, et al. Effects of magnetic resonance imaging on cardiac pacemakers and electrodes. Am Heart J 1997;134:467-473.
Dempsey MF, Condon B, Hadley DM. Investigation of the factors responsible for burns during MRI. J Magn Reson Imaging 2001;13:627-631.
Hartnell GG, Spence L, Hughes LA, et al. Safety of MR imaging in patients who have retained metallic materials after cardiac surgery. AJR 1997;168:1157-1159.
Levine GN, Gomes AS, Arai AE, et al. Safety of magnetic resonance imaging in patients with cardiovascular devices: an American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization. Circulation 2007;116:2878-2891.
Luechinger R, Zeijlemaker VA, Pedersen EM, et al. In vivo heating of pacemaker leads during magnetic resonance imaging. Eur Heart J 2005;26:376-383.
Shellock FG, Valencerina S, Fischer L. MRI-related heating of pacemaker at 1.5- and 3-Tesla: Evaluation with and without pulse generator attached to leads. Circulation 2005;112;Supplement II:561.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.